US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aspire Biopharma Holdings Inc.

0.3825

+0.00611.62%

Post-market: 0.3814-0.0011-0.29%19:56 EDT

Volume:1.88M

Turnover:706.16K

Market Cap:18.94M

PE:-1.00

High:0.3967

Open:0.3890

Low:0.3540

Close:0.3764

52wk High:15.80

52wk Low:0.2012

Shares:49.53M

Float Shares:35.35M

Volume Ratio:0.52

T/O Rate:5.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3817

EPS(LYR):-0.0030

ROE:--

ROA:-64.24%

PB:-1.97

PE(LYR):-128.53

Loading ...

Overview Company News Filings

Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures

Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application

Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025–2026 FDA Submissions

Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches

Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting

Aspire Biopharma files to sell 147.18M shares of common stock for holders

Aspire Biopharma announces initial production order of 2M servings of BUZZ BOMB

Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting

Aspire Biopharma Announces Breakthrough Clinical Trial Results for Sublingual Aspirin, Aiming for Accelerated FDA Approval

Aspire Biopharma Holdings Inc - on Aug 19, Enters Agreement to Sell $9.69 Mln Notes - SEC Filing

THOMSON REUTERS

Aspire Biopharma Secures $9.7M Securities Purchase Agreement with Investors

Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Patent-Pending Sublingual Drug Delivery Technology

Top Midday Gainers

MT Newswires Live

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

Aspire Biopharma Announces Positive Results from Clinical Trial of New Sublingual Aspirin for Heart Attack Treatment

Aspire Biopharma Holdings Inc. to Present at Sidoti Virtual Investor Conference

Aspire Biopharma Hldgs Q2 EPS $(0.04)

Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Annual Report

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.3825,"timestamp":1761940800000,"preClose":0.3764,"halted":0,"volume":1877282,"hourTrading":{"tag":"盘后","latestPrice":0.3814,"preClose":0.3825,"latestTime":"19:56 EDT","volume":15015,"amount":5632.6576,"timestamp":1761955004336},"delay":0,"floatShares":35345600,"shares":49525970,"eps":-0.38171,"marketStatus":"Market Closed","change":0.0061,"latestTime":"10-31 16:00:00 EDT","open":0.389,"high":0.3967,"low":0.354,"amount":706164.3105583,"amplitude":0.113443,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.38171,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1762160400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3764,"preHourTrading":{"tag":"盘前","latestPrice":0.3899,"preClose":0.3764,"latestTime":"09:29 EDT","volume":89267,"amount":34097.1731628,"timestamp":1761917382036},"postHourTrading":{"tag":"盘后","latestPrice":0.3814,"preClose":0.3825,"latestTime":"19:56 EDT","volume":15015,"amount":5632.6576,"timestamp":1761955004336},"volumeRatio":0.520338},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":35345600,"roa":"-64.24%","roe":"--","lyrEps":-0.002976,"volumeRatio":0.520338,"shares":49525970,"dividePrice":0,"high":0.3967,"amplitude":0.113443,"preClose":0.3764,"low":0.354,"week52Low":0.2012,"pbRate":"-1.97","week52High":15.8,"institutionHeld":0,"latestPrice":0.3825,"eps":-0.38171,"divideRate":0,"volume":1877282,"delay":0,"ttmEps":-0.38171,"open":0.389,"prevYearClose":11.5,"prevWeekClose":0.3443,"prevMonthClose":0.206,"prevQuarterClose":0.206,"fiveDayClose":0.3443,"twentyDayClose":0.3838,"sixtyDayClose":0.3334},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2025-10-30","current":-1.00207,"percent":0.654762,"low":-107.647863,"twenty":-36.496931,"median":-1.153491,"eighty":-0.912062,"high":-0.539675,"avg":-13.724862,"sd":20.38052,"marketCap":19513232},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329},{"date":"2025-06-13","current":-1.091781,"twenty":-45.929755,"median":-34.956848,"eighty":-1.13913,"marketCap":18582368},{"date":"2025-06-20","current":-0.913361,"twenty":-45.88526,"median":-32.509654,"eighty":-1.103849,"marketCap":15545618},{"date":"2025-06-27","current":-0.879171,"twenty":-45.613987,"median":-30.966702,"eighty":-1.056614,"marketCap":14963696},{"date":"2025-07-03","current":-0.838948,"twenty":-45.240807,"median":-27.672677,"eighty":-0.926003,"marketCap":14279083},{"date":"2025-07-11","current":-0.994957,"twenty":-44.49445,"median":-25.763721,"eighty":-0.89957,"marketCap":16934405},{"date":"2025-07-18","current":-1.022827,"twenty":-44.487272,"median":-24.235121,"eighty":-0.913361,"marketCap":17408745},{"date":"2025-07-25","current":-1.492005,"twenty":-43.705031,"median":-23.47441,"eighty":-0.913361,"marketCap":25394273},{"date":"2025-08-01","current":-1.094942,"twenty":-43.417971,"median":-12.855253,"eighty":-0.926003,"marketCap":18636159},{"date":"2025-08-08","current":-0.957894,"twenty":-42.341491,"median":-1.730761,"eighty":-0.926003,"marketCap":16303583},{"date":"2025-08-15","current":-1.119076,"twenty":-41.810429,"median":-1.408829,"eighty":-0.936633,"marketCap":19046927},{"date":"2025-08-22","current":-1.407348,"twenty":-41.62384,"median":-1.381965,"eighty":-0.948126,"marketCap":26605351},{"date":"2025-08-29","current":-1.458172,"twenty":-41.494663,"median":-1.401585,"eighty":-0.950712,"marketCap":27566154},{"date":"2025-09-05","current":-1.427258,"twenty":-40.909001,"median":-1.428961,"eighty":-0.956458,"marketCap":26981748},{"date":"2025-09-12","current":-1.182832,"twenty":-39.815341,"median":-1.395821,"eighty":-0.96387,"marketCap":22360975},{"date":"2025-09-19","current":-1.153491,"twenty":-39.515377,"median":-1.375367,"eighty":-0.974558,"marketCap":21806284},{"date":"2025-09-26","current":-0.990278,"twenty":-38.902502,"median":-1.341067,"eighty":-0.987594,"marketCap":18720816},{"date":"2025-10-03","current":-1.100309,"twenty":-38.179108,"median":-1.232741,"eighty":-0.956458,"marketCap":20800907},{"date":"2025-10-10","current":-0.881819,"twenty":-37.978166,"median":-1.192915,"eighty":-0.950195,"marketCap":16670441},{"date":"2025-10-17","current":-0.836759,"twenty":-37.504515,"median":-1.176427,"eighty":-0.934507,"marketCap":15818594},{"date":"2025-10-24","current":-0.880247,"twenty":-36.758157,"median":-1.164494,"eighty":-0.913361,"marketCap":16640725},{"date":"2025-10-30","current":-1.032195,"twenty":-36.496931,"median":-1.153491,"eighty":-0.912062,"marketCap":19513232}],"updateTime":1761946570146},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576064128","title":"Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064128?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:16","pubTimestamp":1760735780,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced that it received a notice from the Nasdaq Stock Market LLC regarding its failure to comply with two key listing requirements: the minimum Market Value of Listed Securities  of $50 million and the minimum bid price rule. The company did not regain compliance within the designated 180-day period, leading Nasdaq staff to notify Aspire that its securities are subject to delisting. Aspire has requested a hearing before the Nasdaq Hearings Panel, which temporarily stays the suspension of its common stock and warrants. The company will present its plan to regain compliance and seek an extension, but there is no assurance that continued listing will be granted or that compliance will be achieved in the allotted time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL2WX1n6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2573672268","title":"Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2573672268","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573672268?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:30","pubTimestamp":1759753832,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its innovative sublingual drug delivery platform. The proprietary technology, which has not yet been presented at scientific conferences, is designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients  by enabling rapid absorption through sublingual blood vessels. Key features of the platform include faster onset of action, reduced drug-food and drug-drug interactions, lower risk of gastrointestinal irritation, and ease of administration, particularly in emergency situations. Aspire believes this advancement could significantly improve the efficacy and safety of a wide range of medications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL2CxrC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2572686796","title":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2572686796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572686796?lang=en_us&edition=fundamental","pubTime":"2025-10-03 23:30","pubTimestamp":1759505417,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference. Aspire Biopharma Holdings Inc. will participate in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025. The company will present updates on its disruptive sublingual drug delivery technology, including its lead programs targeting FDA submission for sublingual high-dose aspirin and a sublingual ED medication in the second half of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 03, 2025, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL1ylrTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2572868547","title":"Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2572868547","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572868547?lang=en_us&edition=fundamental","pubTime":"2025-10-03 02:44","pubTimestamp":1759430656,"startTime":"0","endTime":"0","summary":"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.\n\n\n\nThe Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&amp;P 500 also rose, gaining, 0.07% to 6,715.87.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/10/48002933/crude-oil-down-2-aspire-biopharma-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4600","NVNI","TQQQ","USAW.SI","TSYW.SI","BK4170","BK4007","BK4164","BK4603","BK4144","USJW.SI","ANGO","QLD","BK4595","NVIW.SI","FPAY","PSQ","UFG","ASBP","BK4526","SQQQ",".IXIC","MNQmain","BK4020","BK4082","BK4023","QID"],"gpt_icon":1},{"id":"2572539271","title":"Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025–2026 FDA Submissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2572539271","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572539271?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:30","pubTimestamp":1759321826,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025-2026 FDA Submissions. Aspire Biopharma Holdings Inc.  has announced upcoming milestones for its pipeline of sublingual drug delivery products. The company plans to submit a 505 New Drug Application  to the U.S. Food and Drug Administration  for its high-dose sublingual aspirin in the second half of 2025, following a review of clinical trial results with the agency. Additionally, Aspire intends to finalize the formulation and manufacture of a sublingual semaglutide product and conduct an initial Phase 1 pharmacokinetic clinical cross-over study in the first half of 2026. For its needle-free, rapid-acting erectile dysfunction medication, Aspire plans to develop and validate the manufacturing process and produce a cGMP batch in early 2026, with a Phase 1 clinical test scheduled for the second or third quarter of 2026. Results of these clinical studies have not yet been presented","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL8XFRPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2570830829","title":"Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830829","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830829?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:11","pubTimestamp":1758921075,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has completed private placements with certain investors under a Securities Purchase Agreement, selling notes with an aggregate principal amount of $9,687,500 for a total subscription price of $7,750,000. The first tranche of $4,709,677 was funded on August 19, 2025, and a second tranche of $1,000,000 was funded on September 22, 2025. The document does not specify the number of shares issued or the names of the investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 26,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL5JD0Ln:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2569712988","title":"Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712988","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712988?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:40","pubTimestamp":1758645648,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a Special Meeting of Stockholders to be held on November 4, 2025, in Provo, Utah. The meeting's agenda includes a proposal to grant discretionary authority to the company's board of directors to amend the company's certificate of incorporation, facilitating a reverse stock split of all outstanding shares of Common Stock by a ratio in the range of one-for-five.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 23, 2025, and is solely responsible for the informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL7m9Pfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2568285736","title":"Aspire Biopharma files to sell 147.18M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2568285736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568285736?lang=en_us&edition=fundamental","pubTime":"2025-09-19 05:00","pubTimestamp":1758229215,"startTime":"0","endTime":"0","summary":"16:58 EDT Aspire Biopharma (ASBP) files to sell 147.18M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-147-18m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-147-18m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2567100220","title":"Aspire Biopharma announces initial production order of 2M servings of BUZZ BOMB","url":"https://stock-news.laohu8.com/highlight/detail?id=2567100220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567100220?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:55","pubTimestamp":1758027323,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced a strategic initiative to rapidly increase the production capacity of its BUZZ BOMB single dose caffeine...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-announces-initial-production-order-of-2m-servings-of-buzz-bomb-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-announces-initial-production-order-of-2m-servings-of-buzz-bomb-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2566116637","title":"Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2566116637","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566116637?lang=en_us&edition=fundamental","pubTime":"2025-09-09 05:11","pubTimestamp":1757365875,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a Special Meeting of Stockholders scheduled for November 4, 2025, in Provo, UT. During this meeting, stockholders will vote on granting discretionary authority to the company's board of directors to amend the company's certificate of incorporation. This amendment involves effecting a reverse stock split of all outstanding shares of common stock by a ratio in the range of one-for-five.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL7mkw9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2564888395","title":"Aspire Biopharma Announces Breakthrough Clinical Trial Results for Sublingual Aspirin, Aiming for Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2564888395","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564888395?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:30","pubTimestamp":1756902656,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings, Inc.  has announced positive final results from its randomized, crossover bioavailability trial involving its investigational new sublingual aspirin product. The study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin compared to chewed uncoated aspirin tablets. Results demonstrated that the sublingual aspirin produced higher and more rapid mean plasma concentrations of acetylsalicylic acid, indicating faster inhibition of serum thromboxane B2 , a biomarker for platelet aggregation. This rapid action is crucial during suspected heart attacks to prevent permanent heart muscle damage. Aspire plans to review these results with the U.S. Food and Drug Administration  for a potential regulatory submission for accelerated approval in the third quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL1lpYG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2561283936","title":"Aspire Biopharma Holdings Inc - on Aug 19, Enters Agreement to Sell $9.69 Mln Notes - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2561283936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561283936?lang=en_us&edition=fundamental","pubTime":"2025-08-23 05:20","pubTimestamp":1755897655,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nFWN3UE0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2561128351","title":"Aspire Biopharma Secures $9.7M Securities Purchase Agreement with Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2561128351","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561128351?lang=en_us&edition=fundamental","pubTime":"2025-08-23 05:15","pubTimestamp":1755897356,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings, Inc. recently announced the signing of a Securities Purchase Agreement with a group of investors. Under this agreement, Aspire Biopharma sold notes amounting to $9,687,500 for a subscription price of $7,750,000. The notes, which feature a 20% original issue discount and no interest rate, will mature on February 19, 2026. Additionally, the notes can be converted into common stock starting 31 days from issuance at 80% of the lowest closing price within the preceding five trading days. The company retains the option to prepay these notes at a 20% premium to the principal amount.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL1zks46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2560112561","title":"Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Patent-Pending Sublingual Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2560112561","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560112561?lang=en_us&edition=fundamental","pubTime":"2025-08-20 04:19","pubTimestamp":1755634775,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., listed on Nasdaq as ASBP, has released an investor presentation highlighting its innovative, patent-pending drug delivery technology. This technology is designed for rapid sublingual absorption, enhancing the pharmacokinetic performance of Active Pharmaceutical Ingredients , supplements, and nutraceuticals, increasing bioavailability and improving the speed of onset. Aspire's key products include a lead Rx product, Sublingual High Dose Aspirin, and a lead consumer product, BUZZ BOMB. The presentation emphasizes the company's focus on commercialization through partnerships, licensing, and internal development, with first revenues expected in late 2025. Aspire's market opportunity exceeds $100 billion, as it continues to develop disruptive technologies for fast-acting drug formulations. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL47Z0Qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2560182419","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2560182419","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560182419?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:24","pubTimestamp":1755537882,"startTime":"0","endTime":"0","summary":"Soligenix  said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels.Shares surged 85% as intraday trading volume catapulted to more than 146.2 million from a daily average of about 8 million.Propanc Biopharma  shares soared 131% in heavy trading after midday on Monday following their debut on Nasdaq on Friday.More than 63.3 million shares traded intraday.Aspire Biopharma  said Monday its investigational sublingual aspirin product demonstrated \"higher and more rapid\" mean plasma concentrations of acetylsalicylic acid, compared with standard chewed aspirin tablets.Shares jumped 52%, with intraday trading volume at over 430.7 million from a daily average of about 15 million.Price: 6.63, Change: +3.76, Percent Change: +130.84","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASBP","BK4139","BK4007","PPCB","SNGX"],"gpt_icon":0},{"id":"2560825041","title":"Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August","url":"https://stock-news.laohu8.com/highlight/detail?id=2560825041","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560825041?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:15","pubTimestamp":1755537313,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/08/47191981/crude-oil-moves-higher-us-homebuilder-sentiment-declines-in-august","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4583","RSKD","SQQQ","TSYW.SI","USJW.SI","BK4167","PSQ","TQQQ","BK4139","NVIW.SI","QLD","USAW.SI","MNQmain","NQmain","ASBP","BK4539","QID","GDRX","PPCB","BK4091","EMPD",".IXIC","BK4007"],"gpt_icon":1},{"id":"2560907443","title":"Aspire Biopharma Announces Positive Results from Clinical Trial of New Sublingual Aspirin for Heart Attack Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560907443","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560907443?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520251,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced positive top-line results from a recent clinical trial of their investigational sublingual aspirin product for the treatment of suspected acute myocardial infarction. The trial demonstrated that Aspire's sublingual aspirin provides a higher and more rapid therapeutic impact compared to standard chewed aspirin tablets. The product was found to be safe and well-tolerated in the study. Aspire plans to review these results with the FDA to potentially pursue accelerated approval. The clinical trial, AB-101, was a randomized crossover bioavailability study involving healthy adults, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL6mDT91:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2559765954","title":"Aspire Biopharma Holdings Inc. to Present at Sidoti Virtual Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2559765954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559765954?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:00","pubTimestamp":1755172828,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., a developer of multi-faceted patent-pending drug and supplement delivery technology, will be presenting at the Sidoti Virtual Investor Conference on August 20, 2025. Kraig Higginson, Interim CEO of Aspire, is scheduled to present at 1:45 PM Eastern. Additionally, the company will host virtual one-on-one meetings with investors on August 20 and 21.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL63nrsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2559709984","title":"Aspire Biopharma Hldgs Q2 EPS $(0.04)","url":"https://stock-news.laohu8.com/highlight/detail?id=2559709984","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559709984?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:50","pubTimestamp":1755121808,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Hldgs (NASDAQ:ASBP) reported quarterly losses of $(0.04) per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47109522/aspire-biopharma-hldgs-q2-eps-0-04","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aspire Biopharma Hldgs Q2 EPS $(0.04)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP"],"gpt_icon":0},{"id":"2559843129","title":"Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2559843129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559843129?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:01","pubTimestamp":1755118898,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has filed an amendment to the 10-Q annual report for the financial year ending March 31, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLb41YvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}